Verified factor-similar pair

FSMD vs JHSC

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

SMB
Similarity score
88
Verified similar

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • FSMD has the higher backtested relative Sharpe (0.972 vs 0.661).
  • FSMD has the lower published fee (0.15% vs 0.46%).
  • JHSC has the stronger regression fit (adjusted R-squared 0.964 vs 0.955).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

FSMD

Fidelity Small-Mid Multifactor ETF
SMB
Adj. R2
0.955
Rel. Sharpe
0.972
Mkt beta
0.94
AUM
US$2.3B
MER
0.15%
Valuation
111

JHSC

John Hancock Multifactor Small Cap ETF
SMB
Adj. R2
0.964
Rel. Sharpe
0.661
Mkt beta
0.99
AUM
US$703M
MER
0.46%
Valuation
110

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
FSMD
+0.56
|t|
+10.5
JHSC
+0.65
|t|
+13.9
diff -0.08
HML
FSMD
+0.23
|t|
+5.2
JHSC
+0.21
|t|
+5.0
diff +0.03
RMW
FSMD
+0.15
|t|
+2.8
JHSC
+0.11
|t|
+2.3
diff +0.04
CMA
FSMD
-0.03
|t|
-0.5
JHSC
-0.02
|t|
-0.3
diff -0.01
UMD
FSMD
+0.11
|t|
+3.0
JHSC
+0.04
|t|
+1.2
diff +0.07

Why This Pair Matches

Exposure level
87
Exposure shape
99
Mkt beta diff
0.05
Rel. Sharpe diff
0.311

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

FSMD fund page JHSC fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.